
EVENT INFORMATION
- This is a CME-Accredited Online LIVE Broadcast
- Upon registration, confirmation will be provided via email
- Login information and instructions will be emailed to you prior to the event
Next quote »
"Identification of molecular drivers has resulted in tailored treatments for our patients with non-small cell lung cancer which are not only more effective, but less toxic. It is essential the community oncologist have a keen knowledge of the most current precision testing techniques and incorporate newer therapies to provide state-of-the-art care to patients close to home."
-Makenzi Evangelist, M.D., New York Oncology Hematology
“The landscape of lung cancer with new biomarkers, immunotherapies, and targeted therapies is constantly evolving, and it is a challenge for the community oncologist to integrate and apply this new knowledge in daily clinical practice. Accessible continuing education forums are crucial to support this rapid evolution of cancer care."
-Nischala Ammannagari, M.D., New York Oncology Hematology
Registration
PROGRAM OVERVIEW
TARGET AUDIENCE
LEARNING OBJECTIVES
After participating in this activity, learners will be better able to:
- Understand the current classification system of the lymphoma
- Discuss updated data on novel agents and therapeutic approaches for patients with aggressive lymphoma.
- Discuss current standard of care approach in patient with newly diagnosed and relapsed refractory aggressive B cell lymphoma and T cell lymphoma.
- Understand the diagnostic and management approaches in patient with uncommon presentation of lymphoma and CNS lymphoma.
- Understand the disease process and treatment strategies in patients with Hodgkin Lymphoma.
- Identify the unmet need and upcoming strategies in elderly patients with lymphoma.
- Understand the complex diagnosis paradigm and management of thrombotic microangiopathies